VIP (Vasoactive Intestinal Peptide): What the Research Actually Shows

What It Is

A Naturally Occurring Neuropeptide, Not a Synthetic Construct

VIP is a naturally occurring 28-amino-acid neuropeptide, produced throughout the gut, lungs, and central nervous system under normal physiology. It signals through VPAC1 and VPAC2 receptors, which are Gs-coupled and drive cAMP and PKA activation, and that pathway is well characterized in the immunology literature independent of any specific clinical protocol built around it.

The Evidence

Mechanism, Clinical Trial Data, and Regulatory Status, Graded Separately

Mechanism: Independent Basic-Science Evidence in an Autoimmune Model

Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP. "Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease." Nature Medicine. 2001;7(5):563–568. PMID: 11329057. This study, from a research group independent of the clinical protocol discussed below, found VIP significantly reduced the incidence and severity of arthritis in an animal model, downregulating both the inflammatory and autoimmune components of the disease. It's the basic-science grounding for VIP's anti-inflammatory mechanism, established well before, and independent of, any specific chronic-illness treatment protocol built on top of it.

Animal Model, Mechanistic · Endpoint: Arthritis Incidence and Severity, Immune-Autoimmune Modulation, Independent of Any Clinical Protocol

The Primary Clinical Trial Behind VIP's Best-Known Use

Shoemaker RC, House D, Ryan JC. "Vasoactive intestinal polypeptide (VIP) corrects chronic inflammatory response syndrome (CIRS) acquired following exposure to water-damaged buildings." Health. 2013;5(3):396–401. An open-label study of 20 patients on replacement intranasal VIP for at least 18 months, run by the same group that developed the CIRS diagnostic framework and published in a smaller specialty journal rather than a major peer-reviewed immunology or endocrinology title. No control group, no blinding.

Open-Label, Uncontrolled, Single-Center · N=20 · No Control Group, No Blinding · Same Group That Developed the Underlying Diagnostic Framework

A Correlative Follow-Up, Same Dataset

Ryan JC, Shoemaker RC. "RNA-Seq on patients with chronic inflammatory response syndrome (CIRS) treated with vasoactive intestinal peptide (VIP) shows a shift in metabolic state and innate immune functions that coincide with healing." Medical Research Archives. 2016;4(7). Reports shifts in metabolic and innate immune gene expression correlating with clinical improvement on VIP. Mechanistic support, but it comes from the same single-center, uncontrolled dataset above, not an independent cohort.

Correlative, Same Single-Center Dataset as Above · Not an Independent Replication

Regulatory Listing, Not a Clinical Trial

U.S. Food and Drug Administration. Bulk drug substances used in compounding under Section 503A of the FD&C Act, interim categories. Vasoactive intestinal peptide listed under Category 1 as of the May 14, 2026 update. This confirms VIP's current compounding status, a substance FDA has not flagged as a significant safety risk under its interim policy. It says nothing about clinical efficacy for any condition, and the interim policy itself is explicitly subject to change.

Regulatory Listing, Not Clinical Evidence · Category 1 Under Interim 503A Policy, Subject to Change

Where This Fits Clinically

A Last Step, Not a First-Line Therapy

VIP's most extensively documented clinical use is as the last therapy introduced in the treatment of Chronic Inflammatory Response Syndrome (CIRS), and it isn't used as a first-line or standalone intervention there. It's introduced only after two upstream inflammatory biomarkers, C4a and then MMP-9, have trended toward normal, because introducing an immunomodulatory signal while MMP-9 is still elevated, meaning the blood-brain barrier is still measurably permeable, can produce a paradoxical inflammatory flare rather than resolution. That diagnostic workup, the full biomarker sequence, and the reasoning behind it are covered in full in the companion guide.

The mechanism described above isn't specific to mold exposure, but CIRS is the only context with a published clinical trial and an explicit biomarker gate telling you when it's safe to introduce VIP; using it for another chronic inflammatory pattern would mean extending that same caution by analogy, not following a protocol with its own dedicated evidence.

Sources

References